Actuate Therapeutics Inc·Healthcare
Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical use FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma, NSCLC, colorectal, and pancreatic cancers with initiation planned for 2H 2026 Elraglusib plus RAS inhibitor preclinical results expected in mid-2026 Industry veteran Martin Huber, MD, joins Board of Directors CHICAGO and FORT WORTH, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced key initiatives to advance and expand the potential of the elraglusib development program. Actuate is prioritizing the development of the elraglusib oral tablet formulation, which is intended to enhance patient convenience, broaden potential clinical utility, and improve the pharmacokinetic exposure of elraglusib across multiple oncology indications.
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.
Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies
Twice as many advanced pancreas cancer patients who received an experimental drug developed by Actuate Therapeutics with chemotherapy were alive after one year as those treated with chemo alone, according to results of a mid-stage trial.
CHICAGO and FORT WORTH, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the publication of new data in Nature Medicine from a randomized phase 2 clinical trial (NCT03678883) evaluating elraglusib in combination with the gemcitabine-Nab-paclitaxel (GnP) chemotherapy compared to GnP alone in patients with previously untreated metastatic pancreatic cancer. The peer-reviewed paper (DOI: 10.1038/s41591-026-04327-4), entitled “Elraglusib and Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma: A Randomized Controlled Phase 2 Trial” is available here.
Meg Flippin, Benzinga Staff Writer CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 / Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company advancing elraglusib, a first-in-class, highly selective small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β). This multimodal agent targets tumor survival pathways, DNA damage response, NF-κB signaling and the tumor immune microenvironment, offering a new potential treatment across multiple difficult-to-treat cancers including metastatic pancreatic ductal adenocarcinoma (mPDAC), melanoma, colorectal cancer and sarcomas.
